CR

Craneware PLCLSE Craneware Stock Report

Last reporting period 31 Dec, 2023

Updated 18 Sep, 2024

Last price

Market cap $B

1.057

Small

Exchange

XLON - London Stock Exchange

CRW.L Stock Analysis

CR

Uncovered

Craneware PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

48/100

Low score

Market cap $B

1.057

Dividend yield

1.87 %

Shares outstanding

35.194 B

Craneware Plc engages in the provision of software and support services for the healthcare industry. The firm's Value Cycle Solutions has five product families, which include Patient Engagement, Charge Capture and Pricing, Claims Analytics, Revenue Recovery and Retention, and Cost and Margin Analytics. The Company’s solutions include Chargemaster Toolkit, Trisus Supply, Physician Revenue Toolkit, Reference Plus, Integration for Chargemaster Management, Pharmacy ChargeLink, Trisus Pricing Analyzer, Online Reference Toolkit, Trisus Supplies Assistant, InSight Medical Necessity, Trisus Claims Informatics, InSight Audit, Trisus Healthcare Intelligence, Trisus Pricing Transparency, InSight Denials, Appeals Service, and Customer Success Management and Consulting Services. The company has approximately 2,000 United States hospitals and health systems and almost 10,000 clinics and affiliated retail pharmacies.

View Section: Eyestock Rating